Here are the DEF 14A proxy statements from Actinium Pharmaceuticals, Inc (ATNM) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ATNM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATNM filings page.
Actinium Pharmaceuticals, Inc. (ATNM) scheduled its 2026 Annual Meeting for November 25, 2026, at 9:30 a.m. Eastern Time, at The Garden City Hotel in Garden City, New York. Stockholders will vote on electing David Nicholson and Richard I. Steinhart to three-year director terms, ratifying CBIZ CPAs P.C. as the independent registered public accounting firm for fiscal 2026, and approving named executive officer compensation on a non-binding advisory basis. The Board unanimously recommends voting FOR all three proposals.
Stockholders of record on October 2, 2026 may vote. Actinium reported 31,441,436 common shares issued and outstanding on that date, with one vote per share; a quorum requires at least 34% of voting power. Matt David became CFO in October 2026 after Steve O’Loughlin resigned in February 2026. For 2025, CEO Sandesh Seth’s total compensation was $1,187,320 and former CFO O’Loughlin’s was $546,437. On September 2, 2026, Seth was granted options to purchase 1,130,400 shares and issued RSU awards of 735,600 and 1,027,274 shares, with different vesting schedules.